Study #2021-0578
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients with Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
MD Anderson Study Status
Enrolling
Treatment Agent
Pirtobrutinib, Obinutuzumab, Venetoclax, Valacyclovir, Allopurinol
Description
To learn if the combination of pirtobrutinib (also called LOXO-305), venetoclax, and obinutuzumab is safe and effective when given to patients with chronic lymphocytic leukemia (CLL) or Richter transformation (RT) who have not previously received treatment.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Leukemia
Study phase:
Phase II
Physician name:
Nitin Jain
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.